⇚ Regimen GAZYVA® and LEUKERAN® - for CLL (Induction and Maintenance) Medical Name GAZYVA® (Obinutuzumab) and oral LEUKERAN® (Chlorambucil) for Chronic Lymphocytic Leukemia. Cycles Given 6 Delivery Phases 2 Special Instructions Monitor for Infusion related reactions, Neutropenia and Thrombocytopenia, associated with GAZYVA®. Reactivation of Hepatitis B virus can occur with GAZYVA®. Follow infusion guidelines recommended in the Prescribing Information. Induction treatment consists of D1, D2, D8 and D15 administration of GAZYVA® followed by maintenance treatment given every 28 days. Premedications should include DECADRON® (Dexamethasone) 20 mg IV, TYLENOL® (Acetaminophen) 650-1000 mg PO and BENADRYL® (Diphenhydramine) 50 mg IV. References Goede V, et al. 2013 ASCO Annual Meeting - VIEW External References http://meetinglibrary.asco.org/content/116249-132 - VIEW First Phase Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration GAZYVA® (Obinutuzumab) IV 100 mg D1 N/A NSS 250 cc 240 minutes GAZYVA® (Obinutuzumab) IV 900 mg D2 N/A NSS 250 cc 360 minutes GAZYVA® (Obinutuzumab) IV 1000 mg D8, D15 N/A NSS 250 cc 240 minutes LEUKERAN® PO 0.5 mg/kg D1, D15 N/A N/A N/A N/A Second Phase Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration GAZYVA® (Obinutuzumab) IV 1000 mg D1 q28 NSS 250 cc 240 minutes LEUKERAN® PO 0.5 mg/kg D1, D15 q28 N/A N/A N/A